Minnesota State University, Mankato

Cornerstone: A Collection of Scholarly
and Creative Works for Minnesota
State University, Mankato
All Graduate Theses, Dissertations, and Other
Capstone Projects

Graduate Theses, Dissertations, and Other
Capstone Projects

2021

Cannabis as a Prescription Opioid Substitute for Adults with
Chronic Pain: A Systematic Literature Review
Lani Kranz
Minnesota State University, Mankato

Follow this and additional works at: https://cornerstone.lib.mnsu.edu/etds
Part of the Chemicals and Drugs Commons

Recommended Citation
Kranz, L. (2021). Cannabis as a prescription opioid substitute for adults with chronic pain: A systematic
literature review [Master’s alternative plan paper, Minnesota State University, Mankato]. Cornerstone: A
Collection of Scholarly and Creative Works for Minnesota State University, Mankato.
https://cornerstone.lib.mnsu.edu/etds/1102

This APP is brought to you for free and open access by the Graduate Theses, Dissertations, and Other Capstone
Projects at Cornerstone: A Collection of Scholarly and Creative Works for Minnesota State University, Mankato. It
has been accepted for inclusion in All Graduate Theses, Dissertations, and Other Capstone Projects by an
authorized administrator of Cornerstone: A Collection of Scholarly and Creative Works for Minnesota State
University, Mankato.

Cannabis as a Prescription Opioid Substitute for Adults with Chronic Pain:
A Systematic Literature Review

Lani Kranz
School of Nursing, Minnesota State University, Mankato
NURS 695: Alternate Plan Paper
Dr. Gwen Verchota
April 26, 2021

Abstract
Objective: To determine whether the use of cannabis improves pain control and/or reduces the
amounts of opioids needed to control pain in adults with chronic pain.
Methods: A systematic literature review of research conducted from the past five years. Five
databases were searched, resulting in 14 peer-reviewed articles relevant to the objective.
Results: The majority of the literature reviewed demonstrated the use of cannabis by adults with
chronic pain resulted in better pain control and/or fewer opioids required to control pain in this
population. The two articles which contradicted these findings only evaluated illicit, not medical,
cannabis use by individuals with chronic pain.
Conclusions: Cannabis should be considered as an alternative or adjunct to opioid therapy in
adults with chronic pain. Changes in patient and provider education about cannabis as a therapy
for chronic pain are necessary. The classification of cannabis as a Schedule I controlled
substance by the federal government complicates research, public perception, and patient access
and should be re-evaluated. Further research is indicated in determining the specific types,
strains, and methods of ingestion that are most effective in this population; the sub-types of pain
that are improved with cannabis; what the adverse effects of cannabis use in this population are;
and what barriers exist for providers in recommending cannabis as a treatment option. Evidence
from RCTs, particularly comparing cannabis to opioids, is lacking yet difficult to obtain due to
federal and ethical limitations.

Keywords: cannabis, marijuana, opioid(s), opiate(s), chronic pain, intractable pain, pain
control, prescribed, prescription(s)

Cannabis as an Opiate Substitute for Adults with Chronic Pain:
A Systematic Literature Review
From 1999-2018, nearly 450,000 individuals died from an opioid overdose in the United
States, including from the use of both prescription and illicit opioids (Centers for Disease
Control and Prevention [CDC], 2020). In 2019 alone, almost 50,000 individuals died from
opioid-involved overdoses in the United States (National Institutes of Health [NIH], 2021).
Pharmaceutical companies assured health care providers that prescription opioids such as
oxycodone were not addictive, leading to exponential increases in the prescribing of these
medications for moderate and severe pain beginning in the late 1990s (CDC, 2020). Even after
the CDC released new guidelines for providers in 2016 intended to reduce the number of opioids
prescribed, 191 million opioid prescriptions were still written in 2017 (CDC, 2020). As public
interest in reducing opioid prescriptions has increased, so have the number of states allowing the
legal use of cannabis to treat a range of medical conditions, including chronic pain. Today, 31 of
the 36 states with legalized cannabis use allow cannabis to be used to treat chronic pain, although
the language and restrictions vary from state-to-state (Medical Marijuana Project [MMP], 2021).
Fifteen states allow for adult use of cannabis for any reason, including recreationally and many
individuals who purchase adult-use cannabis report using it to control pain (MMP, 2021). In the
context of this newly expanded access to cannabis for pain control, the CDC’s recommendation
that providers consider other available options for treating chronic pain (Dowell et al., 2016)
supports investigating the efficacy of cannabis in controlling chronic pain and evaluating its
impact on opioid prescriptions for this population.

Background
CDC guidelines define ‘chronic pain’ as pain that has been present for greater than three
months or past the time of normal tissue healing (Dowell et al., 2016). Data from the National
Health Interview Survey indicated that in 2019, 20.4% of adults in the United States had chronic
pain, and 7.4% of adults had ‘high-impact’ chronic pain frequently limiting life or work activities
in the past 3 months (Zelaya et al., 2020). Chronic pain and high-impact chronic pain is
associated with decreased quality of life; increased rates of depression, anxiety, and insomnia;
lost work productivity and increased opioid use dependence (Zelaya et al., 2020). Survey data
indicated that women, adults over the age of 65, and individuals living in rural communities were
more likely to suffer from chronic pain than others (Zelaya et al., 2020).
Many patients affected by chronic pain are prescribed opioid analgesics. Of patients with
chronic pain who are prescribed opioids, approximately 21-29% will misuse these opioids, 4-6%
will transition to heroin use, and 8-12% will develop an opioid use disorder (NIH, 2021). In
2017, 1.7 million adults had a substance use disorder related to prescription opioid pain relievers
(NIH, 2021). Repeated use of opioids over time increases the risk of developing an opioid use
disorder (HHS, 2016). Even patients using opioids appropriately as prescribed are subject to a
wide range of side effects including constipation, nausea, vomiting, sexual dysfunction, sedation,
dizziness, physical dependence, withdrawal syndrome, and respiratory depression (Benyamin et
al., 2008; Woodbury, 2015). Many patients develop tolerance to opioids over time and are
prescribed increasingly larger doses. Some patients paradoxically experience increased pain on
the higher doses of opioids, a phenomenon referred to as opioid-induced hyperalgesia
(Woodbury, 2015). Contrary to public perception of opioids as the gold standard for pain relief,
the CDC stated in its opioid prescribing guidelines for chronic pain that “Evidence on long-term

opioid therapy for chronic pain outside of end-of-life care remains limited, with insufficient
evidence to determine long-term benefits versus no opioid therapy, though evidence suggests
risk for serious harms that appears to be dose-dependent,” (Dowell et al., 2016). The first
recommendation from the CDC within these new guidelines is that “Nonpharmacologic therapy
and non-opioid pharmacologic therapy are preferred for chronic pain…if opioids are used, they
should be used in conjunction with nonpharmacologic and non-opioid pharmacologic therapy, as
appropriate,” (Dowell et al., 2016).
The relatively high risk-benefit ratio of using opioids for chronic pain requires primary
care providers to re-evaluate options for controlling pain in this population. In early 2016 when
the CDC published its recommendations on the prescription of opioids for providers, only 25
states and the District of Colombia provided for the legal use of medical cannabis (Medical
Marijuana Project, 2021). Today, 31 states include a provision for the legal use of medical
cannabis for severe or chronic pain. Even though most states now allow for legalized medical
cannabis to control chronic pain, cannabis remains a Schedule I controlled substance under
Federal Law, placing it in the same class as drugs deemed to have no medical benefit and a high
risk of abuse such as heroin and LSD. Prescription opioids, by contrast, are classified as
Schedule II-V drugs which confers some medical benefit at the expense of varying risks of
abused. Despite its Schedule I classification, 15 states currently allow for legalized recreational
use of cannabis by adults. Many adults in these states purchase cannabis from recreational
dispensaries to be used medicinally, akin to purchasing ibuprofen over the counter instead of
obtaining a prescription for ibuprofen due to ease of access.
Cannabis, also known as ‘marijuana’, refers to the leafy plants Cannabis sativa and
Cannabis indica. Cannabis grows naturally in much of the world and has been used for various

medicinal purposes for thousands of years (Borgelt et al., 2013). The United States
Pharmacopeia included it as a medical compound from 1851 until it was removed in 1942, five
years after it was criminalized, despite objections from the American Medical Association
(Borgelt et al., 2013). Cannabis contains a mixture of chemicals known as cannabinoids.
Examples of cannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the
cannabinoid typically found in the greatest quantity in cannabis and is known to be psychoactive.
It binds to two types of cannabinoid receptors (C1 and C2) in the brain. It is thought that
analgesia created by THC’s binding to the endocannabinoid system in the brain may be the result
of several different mechanisms including modulation of neuronal activity, effects on descending
pain pathways, and inhibition of prostaglandin synthesis (Borgelt et al., 2013). The mechanism
by which CBD works is not completely known, but it is known that it does not bind to the C1 or
C2 receptors like THC and is hypothesized to counteract some of the psychogenic effects of
THC (Borgelt et al., 2013).
There are currently no cannabis products that have been approved for medical use by the
U.S. Food and Drug Administration (Food and Drug Administration [FDA], 2021). Dronabinol
and nabilone are oral medications containing synthetically derived THC that are FDA-approved
prescription medications for nausea and vomiting related to chemotherapy. Dronabinol has also
been approved for anorexia and wasting from AIDS, due to its appetite-enhancing effect. The
only other related product that is FDA-approved is Epidolex, a purified form of CBD (without
THC), indicated for specific severe seizures in children (FDA, 2021). None of these products are
FDA-approved for the treatment of acute or chronic pain (FDA, 2021). Although research has
been done on the above cannabinoids as to their efficacy in relieving pain, for the purpose of this
review we will limit further discussion exclusively to include only cannabis.

The juxtaposition of the federal classification of cannabis as a Schedule I controlled
substance and the increasing availability of legalized medical cannabis as an option for treatment
of chronic pain merits investigation into whether evidence supports its use for this purpose.
Primary care providers, including nurse practitioners, see many patients presenting with chronic
pain in their day-to-day practice. Primary care providers also serve as stewards of public health
who are being urged to assist in the opioid crisis by re-evaluating their prescribing practices
relating to opioids. A review of pertinent literature will aim to answer the clinical question: In
adults with chronic pain, does the use of cannabis improve pain control and reduce the amounts
of opioids required to control pain? The intent of this review is to provide primary care
providers, including nurse practitioners, with evidence-based recommendations for their patients
presenting with chronic pain regarding treatment with medical cannabis.
Methods
Databases and Search Strategies
An extensive literature search was completed between the dates of 10/15/2020 and
11/20/20. Both PubMed and EBSCO Host Databases were included. Within EBSCO Host, the
Academic Search Premier database, CINAHL Plus with Full-Text database, Cochrane Central
Register of Controlled Trials database and the Cochrane Database of Systemic Reviews were
selected for the searches. The searches were restricted to full-text journal articles in the English
Language from the past five years. Specific search restrictions for each database and the general
subjects covered by each database are included in Table 1 of the appendix.
Details on the search terms used and resulting hits in each database are included in Table
2 of the appendix. Titles of articles which were included in searches with less than 25 hits were

scanned and duplicate titles were eliminated. Of the 28 individual articles remaining, the titles
and abstracts were reviewed to see if the article met inclusion or exclusion criteria.
Inclusion and Exclusion Criteria
To most effectively answer the clinical question posed above, pre-determined inclusion
criteria required that the article either: a) examined the effects of cannabis consumption on
chronic pain, b) examined the relationship between cannabis use and prescription opioid use in
patients with chronic pain, or c) examined the relationship between cannabis use and the
amounts of opioids prescribed by providers. Exclusion criteria included a) illicit or nonprescription use of opioids as a variable, or no specification as to whether the opioid was
prescribed, b) a study population that included individuals < 18 years of age, c) no inclusion of
cannabis or its use in the study, d) investigation of cannabis or opioid misuse, e) opinion articles,
f) study or policy proposals. Table 3 of the appendix details specific application of inclusion and
exclusion criteria to each of the 28 articles. Of these, 14 met criteria for inclusion in the final
literature review.
Literature Review Process
The full text of the selected 14 articles was reviewed and analyzed to extrapolate what
populations were being studied, what variables were being investigated, what instruments were
utilized, pertinent clinical findings, implications for practice, and the level of evidence involved.
Table 4 of the appendix summarizes each of these 14 articles in detail.
Methodological Assessment
Several databases were searched using multiple relevant search terms in various
combinations, producing articles which all helped answer the clinical question posed above.
However, this literature review was subject to certain limitations. In wishing to retrieve the most

recent data, the search timeframe was limited to articles published within the last five years.
This may have resulting in missing other pertinent research, albeit older, that could support or
refute the conclusions. Initially, the review was going to be limited to only medicinal cannabis,
but in reading some of the articles it was apparent there were subsets of individuals who would
either qualify for medical cannabis but lived in one of the 15 states where recreational cannabis
was legal and purchased it at the recreational dispensaries instead or those that self-substituted
illicit cannabis for prescription opioids. Hence, the criteria for cannabis to be strictly ‘medical’
was eliminated. Searching more databases may have yielded more articles, as would have not
limiting the search to full text only. This review was completed by one author and having a
second author validate the above searches, articles, and inclusion/exclusion criteria would better
control for potential bias and enhance the validity of the findings, consistent with established
standards for systematic reviews.
Literature Review
Study Characteristics
Most of the studies evaluated were cross-sectional cohort studies or secondary data
analyses of cross-sectional cohort studies. One study was a quasi-experimental differencewithin-differences study, one was a historical cohort study, one study was a secondary data
analysis of a prospective cohort study, and one study was a case report (n=1). Three studies were
qualitative in nature, describing the experience of individuals with chronic pain and cannabis.
Due to the design of the studies retrieved, the highest level of evidence found was the inclusion
of several cross-sectional studies that were Level IV (Melnyk & Fineout-Overholt, 2015). All the
studies reviewed would be considered Level IV, except for the three qualitative studies and the
individual case report, all of which were Level VI (Melnyk & Fineout-Overholt, 2015). One

relevant systemic review and meta-analysis on cannabinoids (Level I) was found while searching
the Minnesota Department of Health website for additional resources (Whiting et al., 2015).
However, because this meta-analysis and systemic review explored all cannabinoids and not just
cannabis, only the information included on the studies involving cannabis was considered so the
overall meta-analysis was not applicable.
Types of Research
While conducting the literature review, it became apparent that the clinical question
posed above could be broken down into two related components. Eight of the articles examined
whether cannabis helped control pain in individuals with chronic pain. Thirteen of the articles
examined whether cannabis use impacted the amount of prescription opioids that were either
used or prescribed for adults. All eight articles which examined whether cannabis helped control
pain also examined whether cannabis use was related to prescription opioid use, so there was
overlap among these eight articles. One qualitative article did not fit directly into either of the
above divisions but provided complementary insight into decreased opioid prescriptions driving
the desire to utilize medical cannabis for a group of adults with chronic pain and was retained for
this reason.
Populations Studied
The populations studied ranged in number from a case study of an individual with acute
on chronic pain (Meng et al., 2016) to a secondary data analysis of 4,840,562 individual records
of commercially insured adults, of which a subgroup of adults with chronic pain that represented
approximately 30% of that number were included (Shah et al., 2019). Eight of the cross-sectional
quantitative studies had an n>1000, while the three qualitative studies had n=15 (Sinha et al.,
2019), n=21 (Gill & Young, 2019), and n=200 (Zaller et al., 2015).

The populations studied fall into four categories: 1) Cannabis users whose reasons for
using were studied, 2) adults with chronic pain who were using cannabis and prescription opioids
together, 3) Medicare patients with chronic pain, and 4) Medicaid patients with opioid
prescriptions. One study only included adults with chronic pain from sickle-cell anemia (Sinha et
al., 2019), and two studies included only adults with HIV and chronic pain (Merlin et al., 2019,
Sohler et al., 2018). The single case study focused on an adult male who had diagnoses of acute
and chronic pain with long-standing opioid use (Meng et al., 2016).
Research Synthesis
Population of Interest
Most of the studies reviewed explicitly limited the population under investigation to
adults with chronic pain. Recall that chronic pain is considered by the CDC to be pain that has
been present for greater than three months or past the time of normal tissue healing (Dowell et
al., 2016), and that in 2019 one-fifth of the US population suffered from chronic pain (Zelaya et
al., 2020). The individuals who were classified as having chronic pain for the purposes of these
studies had a variety of underlying diagnoses, ranging from individuals with chronic low back
pain (Vigil et al., 2017) to individuals affected by sickle cell disease (Sinha et al., 2019) and HIV
(Merlin et al., 2019; Sohler et al., 2018). Some of the studies inferred chronic pain from patients
having prescriptions for opioids (Ishida et al., 2019; Wen & Hockenberry, 2018). The variety of
conditions which could cause chronic pain are numerous and are not differentiated in most of the
studies reviewed. The Minnesota Department of Health, for example, lists 24 primary symptoms
experienced by individuals certified for intractable pain who participated in the medical cannabis
program between Aug 1, 2016 and December 31, 2016 and notes that 15.3% of patients enrolled
in the program were concurrently certified for at least one additional condition (Minnesota

Department of Health [MDH], n.d.a). However, all the studies either involved adults with a
diagnosis of chronic pain, adults who self-identified as having chronic pain, or adults who were
taking cannabis or prescription opioids for pain.
Types of Cannabis
This review was limited to cannabis, however, within the definition of cannabis is a high
degree of variability regarding THC: CBD ratio, strain, method of ingestion, and whether the
cannabis is used legally or illegally. Only one study investigated which types and strains were
most favored by individuals with chronic pain. Baron et al. (2018) reported that individuals with
chronic pain preferred hybrid (37%), indica (25.4%) and sativa (20.2%) types, all of which have
a high ratio of THC: CBD. By contrast, the CBD dominant types were only preferred by 8.2% of
the chronic pain patients, and balanced types containing equal ratios of CBD and THC were also
preferred by 8.2% (Baron et al., 2018). The preferred cannabis strains out of the 42 options
reported by the chronic pain subset were OG Shark (hybrid type), CBD House Blend (CBD
dominant type), and Pink Kush (hybrid type) (Baron et al., 2018). These patients were all
participants in one of Canada’s national medical marijuana programs, Tilray, and the results
highlight how many options exist for users of “medical cannabis.”
The propensity toward high THC: Low CBD ratio is consistent with data from the state
of Minnesota’s medical cannabis program. For the first five months that intractable pain was
certified as a qualifying condition, 57% of purchases were for “very high” THC: CBD products
(MDH, n.d.a). This was followed by 33% of purchases being for products with a balanced (1:1)
THC: CBD ratio (MDH, n.d.a). Notably, several of the other studies included evaluated
recreational or illicit cannabis use, where the specific type or strain would likely be unknown.

The same data set from the MDH also included information on the method of how
medical cannabis was ingested. 54% of purchases were for inhaled cannabis, 39% were for oral
cannabis, with only 6% for oromucosal and 0.6% for topical preparations (MDH, n.d.a). A
survey of 200 adults using medical cannabis at a Rhode Island dispensary revealed the vast
majority smoked (74%) or used vaporized preparations (17%) (Zaller et al., 2015). Nine of the
other studies explicitly noted differences in the method of use.
Some of the studies evaluated the use of cannabis in a non-medical context. This included
illicit use (Campbell et al., 2018, Ishida et al., 2019, Meng et al., 2019, Sohler et al., 2018) and
use of cannabis in Colorado at an adult-use dispensary without a prescription (Bachhuber et al.,
2019). The remainder of the studies evaluated only medical cannabis in their analyses.
Control of Pain
Of the eight studies which examined the relationship between cannabis use and chronic
pain, six found that cannabis use improved pain control and two found that cannabis use had no
positive effect on pain control. Cannabis use was evaluated both in the context of medical
(prescribed) and recreational (adult) use, as some patients reported using cannabis which was not
medically prescribed for symptom control.
Bachhuber et al. (2019) surveyed 1,000 adults purchasing cannabis at a recreational
dispensary in Colorado. Recreational use of cannabis is legal for adults in Colorado. Of the
adults surveyed, 65% reported taking cannabis for pain relief and 74% reported taking cannabis
to help with sleep (Bachhuber et al., 2019). Within the cannabis users taking cannabis for pain,
80% rated it as very or extremely helpful in controlling their pain (Bachhuber et al., 2019).
Difficulty sleeping can be a consequence of chronic pain, and of the users reporting taking
cannabis to promote sleep, 83% found it to be very or extremely helpful for sleep.

Adults who were prescribed medical cannabis were questioned as to their underlying
conditions at a dispensary in Rhode Island (Zaller et al., 2015). The most common reason for use
among the 200 patients surveyed was chronic pain management, with 69% of patients reporting
experiencing chronic pain at baseline (Zaller et al., 2015). 85% of these patients reported that
medical cannabis resulted in feeling “much better” (Zaller et al., 2015)
Of 21 individuals surveyed through a medical cannabis delivery service in California, 10
reported using it for chronic pain (Gill & Young, 2019). One theme that emerged during their
interviews was that cannabis was often used due to clinical failure, defined as the inability of
other medical treatments to control their pain, or to control symptoms such as insomnia that other
treatments did not help with (Gill & Young, 2019). Another theme endorsed by this cohort was
the lack of side effects from using cannabis for pain control compared to other treatments,
including opioids (Gill & Young, 2019). In the case study of a 57-year-old man who suffered
from a complex pain syndrome and then received a liver transplant, his pre-transplant VAS
global pain scores were rated as 5-6/10 with scheduled prescription opioids to control pain. Postoperatively his VAS pain scores were 5-8/10, requiring escalating doses of opioids. After adding
medical cannabis to his pain management profile, his VAS scores averaged 4/10 five months
post-operatively, while on a lower average dose of opioids than pre-operatively (Meng, 2016). A
dramatic reduction in his neuropathic pain scores (hot-burning 1/10, pain caused by light touch
3/10) and continuous pain descriptors (throbbing, gnawing) were noted (Meng, 2016), although
his intermittent pain descriptors (shooting, stabbing, splitting, and sharp) did not change and he
had developed new neuropathic pain descriptors (numbness, tingling) that were not present prior
to his post-operative discharge. He also reported the cannabis helped with sleep, nausea, and
general malaise (Meng et al., 2015).

Out of 9,003 respondents answering a survey about individual perceptions and use of
cannabis, 486 adults reported using both cannabis and regular use of prescription opioids for pain
within the last year (Ishida et al., 2019). The most common reason for substitution of opioids for
cannabis by this subgroup were better control of pain (36%), fewer side effects (32%) and fewer
withdrawal symptoms (26%) (Ishida et al., 2019). While these individuals did not have a specific
diagnosis of chronic pain, their regular use of prescription opioids for pain would imply that they
experienced some degree of chronic pain. Survey responses by 37 chronic pain patients enrolled
in the New Mexico Cannabis Program (MCP) who were regular users of medical cannabis
indicated that they experienced a statistically significant reduction (p<0.001) in pain levels from
pre-enrollment to one year post enrollment with a mean change of -3.4 on a pain scale from 0-10
(Vigil et al., 2017). These patients all were being treated for musculoskeletal pain, with back
pain as the predominant condition (Vigil et al., 2017). On a follow up survey completed by 23
out of the 37 patients to assess quality-of-life indicators, most patients surveyed also reported
improvements in activity levels, social life, ability to concentrate, and overall quality-of-life
(Vigil et al., 2017). None of the 23 respondents believed that using cannabis as a treatment for
pain had negative effects on any of the quality-of-life indicators (Vigil et al., 2017).
A systematic review and meta-analysis of cannabinoids for medical use was not found
during the literature search, likely because the topic was the broader class of cannabinoids and
not limited to cannabis (Whiting et al., 2015). However, this information was discovered in
researching the Minnesota Department of Health website for information on the state’s medical
cannabis program. Although the findings of the systematic review and meta-analysis
demonstrated that there was moderate-quality evidence to support the use of cannabinoids for the
treatment of chronic pain (Whiting et al., 2015), for the purpose of this literature review only the

data from the single study involving cannabis was reviewed. This study showed pain was
improved for chronic pain patients who used cannabis. Compared to the other studies included in
the meta-analysis that used cannabinoids other than cannabis, the study involving cannabis
showed the highest degree of improvement following use (Whiting et al., 2015). This was
measured as the average number of patients reporting a reduction in pain >30% (OR, 3.43[95%
CI, 1.03-11.48]) compared to placebo (n=50) (Whiting et al., 2015).
As explained above, the Minnesota Department of Health website was searched to find
information on the medical cannabis program in Minnesota. Chronic pain was added as a
qualifying condition for medical cannabis in Minnesota in 2020, and prior to that, intractable
pain had been a qualifying condition since 2016 (MDH, 2019a). Intractable pain was previously
defined by state law as pain “whose cause cannot be removed and, according to generally
accepted medical practice, the full range of pain management treatments appropriate for the
patient have been used without adequate result or with intolerable side effects,” (MDH, n.d.b).
The expansion of medical cannabis to include chronic pain has only been in effect since August
1, 2020, so no data is yet available on the experiences of this population. However, state health
commissioner Jan Malcolm stated:
Minnesota’s medical cannabis program tracks patient experiences so we can learn about
the real-world benefits and downsides of using medical cannabis for various conditions.
The generally positive experience patients have had using medical cannabis to treat
intractable pain prompted us to add chronic pain as a qualifying condition. (MDH, 2019a)
.

Between the time intractable pain was added as a condition in August 2016 and when the

most recent survey data was available in June 2017, 29% of the 4060 patients receiving cannabis
for intractable pain experienced a > 30% decrease in pain from baseline within the first four

months in the program, and 36% of these who experienced a > 30% decrease in pain were able to
maintain that level after 4 months, or 11% were able to achieve and maintain a >30% decrease in
pain for 4 months or longer (MDH, 2019b). However, for other related symptoms, intractable
pain patients who reported moderate or severe symptoms of anxiety, lack of appetite, depression,
disturbed sleep, fatigue, nausea, and vomiting saw much greater increases in experiencing a 30%
improvement in these symptoms for 4 months or longer (MDH, 2019b). Thirty-four percent had
> 30% improvement in anxiety, 34% maintained improvement of appetite, 37% for depression,
32% saw continued improvement of insomnia, 23% of fatigue, 40% for nausea and 50% for
vomiting (MDH, 2019b). When intractable pain patients were administered the PEG scale to
assess Pain Intensity, Enjoyment, and General Activity, 22% of patients experienced and
maintained some degree of improvement in their composite score for greater than four months
(MDH, 2019b). For each subset of the PEG scale, 17% of intractable pain patients experienced
and maintained some improvement in pain intensity, 25% experienced and maintained some
improvement in life enjoyment experience, and 26% experienced and maintained some
improvement in general activity interference (MDH, 2019b).
A separate report was compiled by the Minnesota Department of Health (n.d.a) that
summarized the experience of intractable pain patients enrolled in the Medical Cannabis
Program (MCP) during the first five months that intractable pain was a qualifying condition in
Minnesota from August 1, 2016 to December 31, 2016. A total of 2,290 patients were enrolled in
the MCP for intractable pain during this timeframe (MDH, n.d.a). Fifty-four percent of patients
responded to initial baseline surveys and follow-up surveys six months after certification (MDH,
n.d.a). The patient self-reported PEG and symptom scores in this report mirrored the results
described above which included an additional six months of data (MDH, n.d.a). However, a

“very high or high” level of benefit from medical cannabis was reported by 61% of patients
responding. Only 10% of patients believed they experienced “little or no benefit” from the
medical cannabis. Though a decrease in pain severity was the benefit mentioned most often by
patients (64%), improvement in sleep, reductions in anxiety, reduction of other medications and
associated side effects improved mobility and function and improvement of other indicators of
quality of life were all mentioned as secondary benefits of medical cannabis (MDH, n.d.a).
This MDH report (n.d.a) also surveyed all the health care practitioners caring for
intractable pain patients enrolled in the MCP, of which 40% responded. They reported that 41%
of the 489 patients they cared for in the MCP program had a >30% reduction in their pain score 6
months after enrolling in the MCP (MDH, n.d.a) using the same pain scoring system prior to
enrollment in the MCP and at six months afterwards. Forty-three percent of providers believed
their patients experienced a “very-high or high” level of benefit from the medical cannabis, with
only 24% believing their patients experienced “little or no” benefit.
In contrast to the above studies and reports, a four-year prospective study in Australia
(The Pain and Opioids In Treatment [POINT] study) found that in a sample of 1,514 non-cancer,
chronic pain patients who were prescribed opioids, those who reported using cannabis had
greater pain and lower self-efficacy in managing pain scores, and found no evidence that
cannabis use reduced pain severity (Campbell et al., 2018). Likewise, Merlin et al. (2019) found
that in a sample of 433 people living with HIV and chronic pain, the 120 who reported also using
non-medical cannabis in the past three months did not experience a change in their pain severity
with increasing or decreasing their cannabis use during the timeframe. Individuals who had used
marijuana in the past three months were also more likely to report symptoms of anxiety and
depression (Merlin et al., 2019). The most common pain locations for this cohort were low back

and hands/feet (Merlin et al., 2019). Both the Campbell et al. (2018) and Merlin et al. (2019)
studies investigated non-medical cannabis use, as cannabis was illegal for all purposes, including
medical, in Australia during the years the POINT study took place. Using cannabis for medical
purposes was explicitly excluded from the Merlin et al. (2019) study.
Use of Opioids
Like the results for whether cannabis improved pain control or not, 11 of the 13 studies
found the use of cannabis resulted in decreased amounts of opioids used or prescribed to control
pain. Two studies found no such relationship between the cannabis and opioids. These 13 studies
were designed to either allow patients to self-report cannabis use and concurrent prescription use
or to compare the amount of opioid prescribing in states without medical cannabis laws to states
providing for medical cannabis for chronic pain.
Bachhuber et al. (2019) found in their survey of 1,000 adult-use cannabis customers at a
dispensary in Colorado that among the 65% of those who reported using cannabis for pain relief,
88% of those prescribed opioids for pain had either decreased or stopped using opioids since
initiating the use of cannabis. In their survey of medical cannabis users at a dispensary in Rhode
Island, Zaller et al., (2015) found that 55% of the 200 users studied had substituted medical
cannabis for prescription pain relievers, including opioids. Of those endorsing substitution, 92%
reported fewer unwanted side-effects from medical cannabis compared to traditional prescription
pain medications, including opioids (Zaller et al., 2015). Gill and Young (2018) found in their
interviews with patients using a mobile medical cannabis delivery service in California that
seven out of the ten individuals who were prescribed cannabis for chronic pain had stopped using
their prescription pain relievers completely. All the medications referenced were opioids, with
ibuprofen as the only exception (Gill & Young, 2018). Six of these patients stopped using

prescription analgesics due to the undesirable side effect profile and one patient had become
addicted to their prescription pain reliever and decided to stop (Gill & Young, 2018). Themes
that emerged during their interviews included a distrust of the medical field, including physicians
and pharmaceutical drugs, and use of cannabis to treat addiction to prescription opioids (Gill &
Young, 2018).
In a survey of 2,032 patients enrolled in Tilray, one of Canada’s nationally run Medical
Cannabis Programs, chronic pain was the primary diagnosis for 29.4% of the patients (Baron et
al., 2018). Of this subset of chronic pain patients, 53% reported substituting cannabis for
prescription drugs, with opioids representing 73% of the medications substituted (Baron et al.,
2018). Lucas et al. (2019) analyzed responses from the entire cohort of 2,032 patients, regardless
of primary diagnosis, and found that the most common substitution of cannabis was for
prescription drugs (69%), and of those prescription drugs, 35% were opioids. Within the patients
(n=610) who reported substituting cannabis for prescription opioids, 59% had stopped using
opioids entirely (Lucas et al., 2019).
These findings are consistent with the Ishida et al. (2019) study: Among the 486 users of
both prescription opioids for pain and cannabis, 41% reported a decrease or cessation in
prescription opioid use. The case study of a 57-year-old man suffering from complex generalized
abdominal pain prior to liver transplantation illustrated a dramatic reduction in his post-operative
opioid requirements once medical cannabis was added to his pain regimen six-weeks postoperatively (Meng et al., 2015). His pre-operative hydromorphone requirements ranged between
2 mg-8 mg/day, and at six week post-operatively, he was taking approximately 20-30 mg of
hydromorphone/day and unable to resume work as an engineer because he was too drowsy from
the opioids (Meng et al., 2015). Medical cannabis was added to his pain regimen at that point,

and by 12 weeks post-operatively he was weaned down to 6 mg of hydrocodone/day while still
taking the cannabis (Meng et al., 2015). He was also able to resume working because he was no
longer too drowsy to function. In a secondary data analysis of 790 HIV-positive individuals, half
of whom reported chronic pain, Sohler et al. (2018) found that only illicit cannabis was
significantly (OR 0.57, CI 95%: 0.38-0.87) related to lower odds of prescription opioid use when
compared to cigarettes, alcohol, and other illicit drugs.
Wen and Hockenberry’s (2018) review of Medicaid data from 2011 (the first year that
state reporting of Medicaid managed prescription data became mandatory) to 2016 (when the
CDC issued new recommendations restricting opioid prescribing) compared the data from states
with legalized medical and/or recreational (adult-use) cannabis to those without laws for either
medical or adult-use cannabis. Wen and Hockenberry (2018) demonstrated that states with
medical cannabis laws had a 5.88% lower rated of opioid prescribing (95% CI, -11.55% to 0.21%) and states with legalized adult-use marijuana laws had a 6.38% lower rate of opioid
prescribing (95% CI, -12.20% to -0.56%). This study was not explicitly limited to chronic pain
patients but only evaluated opioids that had been prescribed specifically for pain.
The findings for this Medicaid population are consistent with the review of data from
4,840,562 commercially insured individuals between 2006 and 2014 comparing prescription
opioid use in states with and without legal access to medical cannabis (Shah et al., 2019). Shah et
al. (2019) found that in states where medical cannabis was legal, there was a modestly lower rate
of acute, chronic, and high-risk opioid use compared to states without legalized medical
cannabis. Acute opioid use was defined as at least one opioid prescription in the past year,
chronic opioid use was defined as least 90 days of opioid use within 180 days, with no more than
a 30-day gap in prescriptions, and high-risk opioid use was defined as a) at least one day of

overlap between opioid and benzodiazepine prescriptions, or b) maximum daily dose > 120
milligrams of morphine equivalents (MME), or c) diagnosis of a substance use disorder in the
same year as the opioid prescription (Shah et al., 2019). A subgroup analysis of individuals with
at least one non-cancer chronic pain diagnosis also showed lower risks of opioid use in states
with legalized medical cannabis: Opioid use (Diff (95%) CI: 1.230% (1.200%-1.260%); OR
(95% CI): 0.94 (0.92-0.05); chronic opioid use (Diff (95%) CI: 0.279% (0.275%-0.284%); OR
(95% CI): 0.94 (0.91-0.97); high-risk opioid use (Diff (95%) CI: 0.431% (0.423%-0.440%); OR
(95% CI): 0.91 (0.88-0.94) (Shah et al., 2019). A falsification test was also performed, finding no
relationship between the states with medical cannabis use laws and usage of antihypertensive or
antilipidemic drugs (Shah et al., 2019), contrary to the findings for prescription opioids.
Within the state of New Mexico, a preliminary cohort study compared 37 chronic pain
patients that were enrolled in the state’s Medical Cannabis Program (MCP) to 29 chronic pain
patients using prescription opioids who did not enroll in the MCP (Vigil et al., 2017). After 21
months of observing the Prescription Monitoring Program (PMP) records of opioid prescribing
for these patients, MCP enrollment was associated with 17.27 higher odds of opioid prescription
cessation (CI 1.89-157.36, p=0.012), 5.12 higher odds of decreasing daily prescription opioid
doses (CI 1.56-16.88, p=0.007) and a 47-percentage point decrease in daily opioid doses
compared to a mean change of positive 10.4 percentage points in the non MCP group (Vigil et
al., 2017). Monthly trends for the MCP patients were negative over time (-0.64 mg IV morphine,
CI -1.10 to -0.18, p=0.008) but not statistically significant for the non MCP group (Vigil et al.,
2017).
Again, the Minnesota State Department of Health website was reviewed for information
that may not have been discovered during the literature search. The only data found that

examines the effect of medical cannabis on prescription opioid use is found in the report on the
first five months that intractable pain was included as a qualifying condition in Minnesota
(MDH, n.d.a). Of the 586 responses received from health care practitioners caring for these
patients, 221 indicated that opioid use was reduced six months after enrolling in the medical
cannabis program. Three hundred and fifty-three patients were known to be taking opioids at
baseline from self-reporting, so if only those patients are considered, 221/353, or 63% were able
to reduce or stop using opioids after six months of cannabis (MDH, n.d.a). Of the 221 patients
who had a decrease in opioid use, 58% reduced their use of at least one opioid by 50% or more
during the six-month period (MDH, n.d.a). A review of resources on the MDH website revealed
a relevant article (Bradford et al., 2018) that did not appear in the database searches, possibly
because the full text was not available within the databases searched. Bradford et al. (2018)
completed a longitudinal analysis of daily doses of prescription opioids filled in Medicare Part D
from 2010-2015 and compared states with medical cannabis laws (MCL) to those without MCL.
States with active medical cannabis dispensaries saw 3.742 million fewer daily doses per year of
opioids filled (CI 95%, -6.289 to -1.194) out of an average of 23.08 million daily doses per year.
Results varied between types of opioid, with statistically significant negative associations for
hydrocodone and morphine in states with MCL (Bradford et al., 2018).
An alternative perspective was explored in the qualitative study exploring the experiences
of adults living with chronic pain related to sickle cell disease after the implementation of the
CDC recommendations for restricted opioid prescribing. Fifteen adults interviewed felt that the
new restrictions had limited their access to, and amounts of, opioids prescribed to control their
chronic pain (Sinha et al., 2019). They reported wishing to discuss other options for pain control,
specifically cannabis, with their provider but felt their provider neglected to discuss adequate

pain control or comprehensive care with them (Sinha et al., 2019). The patients cited difficulty
obtaining adequate amounts of opioids, intolerable side effects associated with opioids, and a
desire to be “off” opioids as their reasons for wanting to explore medical cannabis (Sinha et al.,
2019). These are patients who would likely intentionally decrease their opioid use in favor of
using medical cannabis, but they lacked direction from their provider on how to explore this as
an option.
Like the investigation into the relationship between cannabis use and pain control, the
same two studies that found cannabis did not improve pain control also found no association
between using cannabis and the amounts of opioids prescribed for chronic pain patients. The
POINT study, conducted in Australia on 1,514 patients with chronic pain taking prescription
opioids found no evidence that cannabis use reduced the use of prescribed opiates or resulted in
increased rates of opioid discontinuation (Campbell et al., 2018). Merlin et al. (2019) concluded
in their study of 433 individuals living with chronic pain and HIV that cannabis use was not
associated with either higher rates of opioid cessation or lower odds of opioid initiation. As
mentioned in the preceding section, both studies explicitly investigated recreational cannabis use,
which was illegal at the time of the POINT study in Australia.
Gaps in Literature
The most prominent areas where the literature was lacking information was a) on the
specific strains, types, strength, and method of ingestion of cannabis, b) explicit detail on the
types of pain experienced by individuals experiencing chronic pain, and c) head-to-head
comparisons effectiveness of cannabis vs. opioids is in clinical trials. Only one study
investigated which strains of cannabis are preferred by those with chronic pain (Baron et al.,
2018); this same study noted that of the larger sample surveyed, 42 different strains were

mentioned, giving people many options when it comes to selecting cannabis. Only the single
case study investigated which types of pain were improved after adding cannabis (Meng et al.,
2016) by using descriptors such as “burning,” “stabbing,” etc. ‘Pain’ can refer to many types of
unpleasant feelings and it would be beneficial to understand what types of pain are improved by
cannabis. None of the studies compared the effectiveness of cannabis to opioids in head-to-head
clinical trials. The federal classification of cannabis as a Schedule 1 substance presents legal and
logistical difficulties in accomplishing this at the present time. The Minnesota Department of
Health also notes in their evaluation of cannabis-related studies that because most intractable, or
chronic, pain patients are experiencing pain prior to starting cannabis, it is usually only studied
as an adjunct treatment (MDH, n.d,a). Regardless, if feasible to study, this information would be
helpful for both practitioners and patients in understanding what their best options may be for
pain control.
Discussion
In the middle of the opioid crisis, researching alternatives to treat pain, particularly
chronic pain, is of utmost importance to all primary care providers, including nurse practitioners.
The literature reviewed for this article supports the consideration of cannabis for the treatment of
chronic pain, both for its value in relieving pain with relatively few side effects and for its role in
potentially lowering opioid requirements. Chronic pain is multifaceted and can be debilitating.
Nearly all studies reviewed showed that for some adults with chronic pain, control of their pain
improved with the use of cannabis. The only two studies which did not show improvement in
pain for adults with chronic pain after using cannabis considered cannabis use that was illegal in
one study (Campbell et al., 2018), and either illegal or recreational in the other study, but
specifically not prescribed medically (Merlin et al., 2019). It is important to consider that the use

of cannabis and its effects on pain could be underreported in these two studies due to its legal
status at the time.
In addition to improving pain for patients with chronic pain, it was evident in the
literature that for some individuals, cannabis also help improve other related symptoms such as
insomnia (Bachhuber et al., 2019; Gill & Young, 2019; MDH, n.d.b), nausea and malaise (Meng
et al., 2016), depression (Sinha et al., 2019), concentration (Meng et al., 2016; Vigil et al., 2017)
and anxiety (MDH, n.d.b; Sinha et al., 2016). In contrast, Campbell et al. (2018) demonstrated in
the POINT study that patients using illicit cannabis and prescription opioids had higher
generalized anxiety severity scores than patients taking prescription opioids who did not use
illicit cannabis, begging the question of whether the anxiety was related to the use of an illicit
substance. While improvement, or lack thereof, of related symptoms was not the focus of this
literature review, they are important factors in evaluating quality-of-life for these patients.
Except for the Campbell et al. (2018) study, all the studies that mentioned these quality-of-life
indicators reported that they were improved with the use cannabis for adults with chronic pain.
Perhaps even more significant were the adverse effects of taking opioids that many
chronic pain patients reported. Negative side effects from the use of prescription opioids (Gill &
Young, 2019; Ishida et al., 2019; Lucas et al., 2019; Meng et al., 2016; MDH, n.d.a; Sinha et al.,
2019; Zaller et al., 2015) were reported by several studies as reasons patients wished to use
cannabis instead of opioids. Several other studies mentioned a desire by patients simply to be
“off” opioids, whether from concerns over addiction (Gill & Young, 2019; Sinha et al., 2019;
Zaller et al., 2015) or dislike of withdrawal symptoms (Lucas et al., 2019). Knowing that the
American Association of Family Physicians (2016) affirmed that “regular opioid use, including
use in an appropriate therapeutic context, is associated with both tolerance and dependence,”

every effort should be made to consider cannabis as an alternative for controlling pain for
individuals who chronically use opioids, especially for those who express a desire to do so.
Several of the studies evaluated cannabis that was medically ordered, and several of the
studies evaluated cannabis that was purchased for ‘recreational’ purposes, including at adult-use
dispensaries (Bachhuber et al., 2019) or illicitly (Campbell et al., 2018). The advantage of
purchasing either medical-grade cannabis or legal adult-use cannabis through dispensaries is the
ability to purchase specific strains or types, including various THC: CBD ratios, which may be
more helpful in controlling pain for this population. The problem with cannabis obtained through
illicit means is that the strength and composition are usually unknown. However, regardless of
the composition of cannabis or the source, our review suggests that for some people, it improves
pain. The prevalence of people substituting non-medically indicated cannabis (Bachhuber et al.,
2019; Ishida et al., 2019; Sohler et al., 2018) is a testament that individuals are already exploring
this as an option. Additional research is needed to be able to fine-tune the strain and type of
cannabis to the type of pain and type of symptom improvement the patient needs.
In examining substitution of cannabis for opioids, most of the studies similarly found that
some people with chronic pain reduce their opioid use or stop using opioids altogether to control
their pain when also taking cannabis. This held true when patients self-reported opioid use
(Bachhuber et al., 2019; Baron et al., 2018; Ishida et al., 2019; Lucas et al., 2019; Sohler et al.,
2018; Zaller et al., 2015) and when prescription records for opioids were reviewed for patients
either using medical cannabis or in states which allowed medical cannabis (Bradford et al., 2018;
Meng et al., 2016; Shah et al., 2019; Vigil et al., 2017; Wen & Hockenberry, 2018). One caveat
to consider in respect to the studies reviewing state-level data comparing opioid prescription
rates in states with and without medical cannabis legalization is that correlation does not equal

causation. However, this correlation held true when records were reviewed for Medicaid patients
at the federal level (Wen & Hockenberry), Medicare Part D patients at the federal level
(Bradford et al., 2018) and in a nationwide sample of 10% of commercially insured adults (Shah
et al., 2019), suggesting a strong pattern of decreased opioid prescribing when medical cannabis
is a legal option for pain control.
The opioid-sparing effect of using cannabis for the treatment of pain may be attributed to
a synergistic relationship between cannabis and opioids. CB1 receptors are 10 times denser than
mu-opioid receptors in the brain, and are often found in the same areas, including those areas
associated with pain pathways (Baron et al., 2018). Cannabis use does not increase opioid levels
in the blood (Baron et al., 2018), reducing the concern for increased opioid side effects including
respiratory depression. Notably, a pre-clinical study found that the median effective dose (ED50)
of morphine given with THC is 3.6 times lower than the ED50 of morphine alone (Baron et al.,
2018). Even if the exact physiological mechanism is unknown, the evidence reviewed in this
literature affirms that for some people with chronic pain, opioid requirements are decreased
when used in conjunction with cannabis.
The paucity of meta-analyses, systematic reviews, and randomized controlled studies
available on cannabis and chronic pain is partially hampered by federal restrictions on research
involving cannabis due to its Schedule I classification by the FDA. Level I and II evidence such
as this would strengthen the findings of the research discussed in this review, the majority of
which was Level IV.
Future Implications
Recommendations for Education

Both primary care providers and patients would benefit from education regarding not
only the benefits of cannabis as a treatment option for chronic pain, but education as to the
processes of certification, registration, and procurement of cannabis. Sickle cell patients with
chronic pain felt that their providers were focused on reducing the amounts of opioids
prescribed, but neglected to discuss adjunct or alternative therapies, including cannabis, during
appointments (Sinha et al., 2019). The benefits of using for cannabis for the treatment of chronic
pain are detailed in the previous sections, but the logistics of obtaining medical cannabis merits
explanation.
In Minnesota, cannabis is legally available for treatment of 15 medical conditions,
including intractable pain and chronic pain (MDH, n.d.b). For a patient to obtain medical
cannabis, a physician, PA, or APRN must conduct a physical examination, review of pertinent
records, and certify the patient as having a qualifying condition (Institute for Clinical Systems
Improvement [ICSI], 2015). The provider only certifies that the patient has a qualifying
condition under state law, they do not “prescribe” cannabis. A provider must be registered with
the state of Minnesota’s Office of Medical Cannabis (OMC) to certify a patient as having a
qualifying condition. The patient, once certified, also registers with the OMC. After paying an
enrollment fee, they can visit one of the 13 Cannabis Patient Centers located throughout the state
to meet with a licensed pharmacist to determine the best dose, type, and frequency based on the
patient’s condition and symptoms (ICSI, 2015), and the cannabis is dispensed to the patient.
Patients wishing to continue using medical cannabis must be re-certified annually by a registered
provider. Providing education to all primary care providers regarding this process would help
guide discussion with their patients regarding cannabis as an option for pain control.
Information for providers and patients is available on the Minnesota Department of Health’s

website on this process (ICSI, 2015) but it is unknown how widely this information has been
disseminated.
Recommendations for Clinical Practice
In accordance with the 2016 CDC guidelines suggesting opioids not be used as a first-line
treatment for patients with chronic pain (Dowell, 2016), primary care providers, including nurse
practitioners, should be familiar with the use of cannabis as an alternative to or in conjunction
with opioids. They also need to be familiar with the process of registering as a provider and
certifying patients with the OMC so that they can effectively address the needs of their patients
with chronic pain. Since the MDH does not maintain a list of providers who are registered with
the OMC, there is no way for patients to know in advance of their appointment whether their
primary care provider can certify them for medical cannabis.
In Minnesota in 2019, there were 24,643 physicians with active state licenses, 3209
actively licensed physician assistants (PAs), and 8,849 actively licensed Advanced Practice
Registered Nurses (APRNs) for a total of 36,701 licensed providers (MDH, 2019c; MDH 2019d;
MDH, 2019e). However, as of March 11, 2020, only 1,865 of these providers were registered
with the OMC and eligible to certify patients for medical cannabis (MDH, 2021). This represents
only 5% of all licensed providers in the state of Minnesota. In the first five months that
intractable pain was included as a certifiable condition in Minnesota, only 9% of the 265
providers certifying these intractable pain patients were APRNs (MDH, n.d.a). Of the 226
physicians certifying patients for intractable pain during that timeframe 52% listed a specialty in
primary care or family medicine (MDH, n.d.a). The impetus is on providers, particular in
primary care and nurse practitioners, to register with the OMC within this state so that they can
certify patients with chronic or intractable pain that could potentially benefit from medical

cannabis. They should also be knowledgeable about the effects of cannabis, both beneficial and
adverse, so they can have evidence-based discussions with their patients about the best approach
to manage their pain.
Recommendations for Policies
The most important policy concern related to using cannabis as a treatment for pain is its
FDA classification as a Schedule I controlled substance. To legitimize cannabis as a valid
medical treatment, its classification must reflect the existing evidence showing benefit from its
use in controlling pain for patients with chronic pain, and therefore be changed. The
classification of cannabis as a Schedule I controlled substance currently hampers the ability to
research it, even within states that allow for legal medical use of it. Providers are placed in an
undesirable position of certifying a patient for a condition for a legal treatment at the state level,
knowing it is not FDA approved or even legal at the federal level. The fear of using something
deemed illegal at the federal level may also deter patients who would otherwise consider
cannabis as an option for controlling pain. Even individuals who use cannabis for medical
purposes in states where it is legal are prohibited from owning firearms by the federal
government due to cannabis’ status as a Schedule I controlled substance (MDH, n.d.c). Because
opioids are classified as Schedule II and lower, there are no limitations on firearm possession if
an adult is prescribed an opioid. Individuals with chronic pain are more likely to reside in rural
areas (Zelaya et al., 2020), a demographic often associated with increased rates of firearm
possession, so limitations on their rights to bear arms may be a considerable factor in deciding
whether to use medical cannabis for those who may need it the most.
Another policy revision that merits consideration is the legalization of cannabis for adultuse, or recreational use, in addition to medical use. Based on the patterns noted in the research of

the use of recreational marijuana to treat pain (Bachhuber et al., 2018) and self-substitution of
cannabis for opioids with non-medical cannabis (Ishida et al., 2019; Sinha et al., 2019; Sohler et
al., 2018), it is an idea that may warrant careful appraisal. With only five percent of current
providers in Minnesota registered to certify conditions for medical cannabis, and no centralized
listing to access the providers who are certified, the barriers to obtaining medical cannabis are
self-evident (MDH, 2019c; MDH, 2019d; MDH, 2019e). Medical cannabis is not covered by
insurance in the state of Minnesota (MDH, n.d.c), so persons using medical cannabis are paying
face value for their cannabis even though it requires at least one visit to a provider for initial
certification, a $200 enrollment fee in the Medical Cannabis Program, and annual visits to a
provider to be re-certified (MDH, n.d.c). If the cost is the same to the individual regardless of
whether it is deemed medical or not, opening cannabis up to recreational use may remove some
of these barriers preventing chronic pain patients from exploring this as an option.
Following from this, if medical cannabis is to be considered a legitimate treatment for
pain, it should also be covered both by federal and state programs, including Medicare and
Medicaid, and private insurance companies as such. Opioids are covered under most insurance,
so cost and accessibility at the present time may dissuade patients who could benefit from
cannabis from considering this as an alternative or adjunct to chronic opioid use. For example,
generic oxycodone costs anywhere from a $0-$20 co-pay under Medicare with 99% of Medicare
Part D and Medicare Advantage plans covering it (GoodRx, 2020). By contrast, no insurance
companies in the state of Minnesota currently cover medical cannabis. If providers are
recommending alternatives to opioids for controlling pain in patients with chronic pain, it
follows that those alternatives should be covered similarly to the coverage of opioids.

Recommendations for Research
As discussed earlier, further research is indicated in three primary areas for which the
literature is lacking. The first is specificity relating to cannabis composition and method of
ingestion to best match specific symptoms of pain to the most effective type of cannabis. Baron
et al. (2018) began exploring this in their investigation of preferred strains of cannabis for
chronic pain patients, and if cannabis is to be considered as a valid treatment for pain, it merits
the same kind of research into how best to achieve that as other pharmaceutical options have
done in the past. The second area in which further research is indicated is to further differentiate
what specific types of pain are improved with cannabis. Meng et al. (2016) detailed this in a case
study, but this type of research needs to be extended to large studies investigating sub-types of
pain and their response to cannabis. The third area in which a strong indication for additional
research is present is the need for randomized clinical trials comparing cannabis directly to
opioids to determine what is the most effective means of controlling pain. The evidence
reviewed above strongly suggests that cannabis not only helps improve pain in some people, but
also allows some people to decrease the amounts of opioids necessary to control their pain.
Except for personal experiences recounted during some of the qualitative studies (MDH, n.d.b;
Sinha et al., 2019; Zaller et al., 2015), none of the studies examined the efficacy of opioids
compared to cannabis. Particularly absent is the availability of data from RCTs which would
give additional insight into which treatment is more effective. Legal and ethical limitations
prohibit this from being easily accomplished at the present time.
Research is also needed to determine what the potential adverse effects of cannabis are
when used as a treatment for chronic pain. Examining this in detail exceeds the scope of this
paper, but it is an important consideration in recommending cannabis as a treatment. Even

though no deaths have definitively been linked to an overdose of cannabis or cannabinoids it is
known that multiple adverse effects may occur, including impairment of judgement, memory,
motor skills and driving ability (Incze et al., 2020). It is also known that, like opioids, cannabis
use can be habit-forming over time (Incze et al., 2020) although this is usually examined in
context of recreational use. Research on not only the positive, but negative effects of medical
cannabis in both the short and long term would help clinicians feel more confident in
recommending this as a treatment.
As the data from Minnesota suggests, few providers are registered to certify patients with
conditions allowing them to access medical cannabis. Research into what barriers exist to
prevent providers from registering with the OMC in Minnesota would be helpful in widening the
circle of providers who are able to recommend this as an option for patients with chronic pain.
Conclusion
A review of the most recent literature suggests that in adults with chronic pain, cannabis
both improves control of pain and reduces the amounts of opioids necessary to control pain in
some individuals. With the 2016 CDC recommendation that opioids should not be a first line
treatment for chronic pain (Dowell et al., 2016), cannabis could and should be considered by
primary care providers, including nurse practitioners, as a viable alternative to or adjunct to
opioids for control of pain in this population. Changing the federal classification of cannabis
from a Schedule I controlled substance to one that more accurately reflects its medical value
would increase research opportunities and improve access for many adults who may benefit from
cannabis as a treatment for chronic pain. Health care providers, particularly nurse practitioners
and those working in primary care, should be familiar with the associated provider registration

and patient certification processes related to providing access to medical cannabis for their
patients who could benefit from it.

References
American Association of Family Practice Physicians. (2016). Chronic pain management and
opioid misuse: A public health concern (position paper).
https://www.aafp.org/about/policies/all/chronic-pain-management-opiod-misuse.html
Bachhuber, M., Arnsten, J. H., & Wurm, G. (2019). Use of cannabis to relieve pain and promote
sleep by customers at an adult use dispensary. Journal of Psychoactive Drugs, 51(5),
400–404. https://doi.org/10.1080/02791072.2019.1626953
Baron EP, Lucas P, Eades J, Hogue O. (2018). Patterns of medicinal cannabis use, strain
analysis, and substitution effect among patients with migraine, headache, arthritis, and
chronic pain in a medicinal cannabis cohort. J Headache Pain. 2018 May 24;19(1):37.
https://doi.org/10.1186/s10194-018-0862-2
Benyamin, R., Trescot, A. M., Datta, S., Buenaventura, R., Adlaka, R., Sehgal, N., Glaser, S. E.,
& Vallejo, R. (2008). Opioid complications and side effects. Pain Physician, 11(2 Suppl),
S105–S120.
Borgelt, L. M., Franson, K. L., Nussbaum, A. M., & Wang, G. S. (2013). The pharmacologic and
clinical effects of medical cannabis. Pharmacotherapy: The Journal of Human
Pharmacology and Drug Therapy, 33(2), 195-209. https://doi.org/10.1002/phar.1187
Bradford, A. C., Bradford, D., Abraham, A., & Adams, G. (2018). Association between US state
medical cannabis laws and opioid prescribing in the Medicare Part D population. JAMA
Intern Med, 178(5), 667-673. http://doi.org/10.1001/jamaintermed.2018.0266
Campbell, G., Hall, W. D., Peacock, A., Lintzeris, N., Bruno, R., Larance, B., Nielsen, S.,
Cohen, M., Chan, G., Mattick, R. P., Blyth, F., Shanahan, M., Dobbins, T., Farrell, M., &
Degenhardt, L. (2018). Effect of cannabis use in people with chronic non-cancer pain

prescribed opioids: Findings from a 4-year prospective cohort study. Lancet Public
Health, 3(7), e341-e350. https://doi.org/10.1016/S2468-2667(18)30110-5
Centers for Disease Control and Prevention. (2020). Opioid overdose: Understanding the
epidemic. https://www.cdc.gov/drugoverdose/epidemic/index.html
Dowell, D., Haegerich, T. M., & Chou, R. CDC Guideline for Prescribing Opioids for Chronic
Pain. (2016). MMWR Recomm Rep 2016;65(RR-1),1–49.
https://dx.doi.org/10.15585/mmwr.rr6501e1external icon
Gill, H. K., & Young, S. D. (2019). Exploring cannabis use reasons and experiences among
mobile cannabis delivery patients. Journal of Substance Use, 24(1), 15–20.
https://doi.org/10.1080/14659891.2018.1489012
GoodRx. (2021). Oxycodone. https://www.goodrx.com/oxycodone/medicare-coverage
Incze, M. A., Slawek, D., & Cunningham, C. O. (2020). What should I know about medical
cannabis? JAMA Internal Medicine Patient Page.
https://doi.org/10.1001jamainternmed.2020.0018
Institute for Clinical Systems Improvement. (2015). Health care practitioner guidance for
Minnesota’s Medical Cannabis Program.
https://www.health.state.mn.us/people/cannabis/docs/practitioners/icsiguide.pdf
Ishida, J. H., Wong, P. O., Cohen, B. E., Vali, M., Steigerwald, S., & Keyhani, S. (2019).
Substitution of marijuana for opioids in a national survey of US adults. PLoS ONE,
14(10), 1–8. https://doi.org/10.1371/journal.pone.0222577
Lucas P, Baron EP, Jikomes N. (2019). Medical cannabis patterns of use and substitution for
opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results

from a cross-sectional survey of authorized patients. Harm Reduct J. 2019 Jan
28;16(1):9. https://doi.org/10.1186/s12954-019-0278-6
Medical Marijuana Project. (2021). State-by-state language allowing severe pain.
https://www.mpp.org/issues/medical-marijuana/state-state-language-allowing-severe-pain
Melnyk, B. M., & Fineout-Overholt, E. (2015). Evidence based practice in nursing and
healthcare: A guide to best practice (3rd ed.). Wolters Kluwer.
Meng, H., Hanlon, J., Katznelson, R., Ghanekar, A., McGilvray, I., Clarke, H., & Hanlon, J. G.
(2016). The prescription of medical cannabis by a transitional pain service to wean a
patient with complex pain from opioid use following liver transplantation: A case report.
Canadian Journal of Anaesthesia.
Merlin J. S., Long, D., Becker, W. C., Cachay, E. R., Christopolous, K. A., Claborn, K. R.,
Crane, H. M., Edelman, E. J., Lovejoy, T.I., Mathews, W. C., Morasco, B. J., Napravnik,
S., OʼCleirigh, C., Saag, M. S., Starrels, J. L., Gross, R., & Liebschutz, J. M. (2019).
Marijuana use is not associated with changes in opioid prescriptions or pain severity
among people living with HIV and chronic pain. J Acquir Immune Defic Syndr, 81(2),
231-237. https://doi.org/10.1097/QAI.0000000000001998
Minnesota Department of Health. (n.d.a). Intractable pain patients in the Minnesota Medical
Cannabis program: Experience of enrollees during the first five months.
https://www.health.state.mn.us/people/cannabis/docs/about/ipreport.pdf
Minnesota Department of Health. (n.d.b). Medical cannabis qualifying conditions.
https://www.health.state.mn.us/people/cannabis/patients/conditions.html
Minnesota Department of Health. (n.d.c). What patients should know before enrolling:

Frequently asked questions.
https://www.health.state.mn.us/people/cannabis/patients/patientfaq.html
Minnesota Department of Health. (2019a). MDH News Release. Medical cannabis program to
add chronic pain, macular degeneration as qualifying conditions.
https://www.health.state.mn.us/news/pressrel/2019/cannabis120219.html
Minnesota Department of Health. (2019b). Benefits reported on patient self-evaluation:
Patients with first enrollment July 2015-June 2017.
https://www.https://www.health.state.mn.us/people/cannabis/docs/about/cohort/c2015_20
17_benefitspse.pdf
Minnesota Department of Health. (2019c). Overview of the physician workforce 2019.
https://www.health.state.mn.us/data/workforce/phy/docs/cbphys.pdf
Minnesota Department of Health. (2019d). Minnesota’s physician assistant (PA) workforce.
https://www.health.state.mn.us/data/workforce/phy/docs/cbpa.pdf
Minnesota Department of Health. (2019e). Minnesota’s Advanced Practice Registered Nurse
workforce.
https://www.health.state.mn.us/data/workforce/nurse/docs/2019aprnb.pdf
Minnesota Department of Health. (March 11, 2021). Medical cannabis weekly updates of
registration counts.
https://www.health.state.mn.us/people/cannabis/about/medicalcannabisstats.html

National Institutes of Health. (2021). Opioid overdose crisis.
https://www.drugabuse.gov/drug-topics/opioids/opioid-overdose-crisis

Shah, A., Hayes, C. J., Lakkad, M., & Martin, B. C. (2019). Impact of medical marijuana
legalization on opioid use, chronic opioid use, and high-risk opioid use. JGIM: Journal of
General Internal Medicine, 34(8), 1419–1426.
https://doi.org/10.1007/s11606-018-4782-2
Sinha, C. B., Bakshi, N., Ross, D., & Krishnamurti, L. (2019). Management of chronic pain in
adults living with sickle cell disease in the era of the opioid epidemic: A qualitative
study. JAMA Netw Open. 2019 May 3;2(5), e194410.
https://doi.org/10.1001/jamanetworkopen.2019.4410
Sohler, N. L., Starrels, J. L., Khalid, L., Bachhuber, M. A., Arnsten, J. H., Nahvi, S., Jost, J., &
Cunningham, C. O. (2018). Cannabis use is associated with lower odds of prescription
opioid analgesic use among HIV-Infected individuals with chronic pain. Substance Use
& Misuse, 53(10), 1602–1607. https://doi.org/10.1080/10826084.2017.141640
United States Department of Health and Human Services. (2016). Facing addiction in America:
The Surgeon General’s spotlight on opioids.
https://addiction.surgeongeneral.gov/sites/default/files/OC_SpotlightOnOpioids.pdf
United States Food and Drug Administration. (2021). FDA regulation of cannabis and cannabisderived products, including cannabidiol (CBD). https://www.fda.gov/newsevents/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-productsincluding-cannabidiol-cbd#approved
Vigil, J. M., Stith, S. S., Adams, I. M., & Reeve, A. P. (2017). Associations between medical
cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study.
PLoS ONE, 12(11), 1–13. https://doi.org/10.1371/journal.pone.0187795

Wen, H. & Hockenberry, J. M. (2018). Association of medical and adult-use marijuana laws with
opioid prescribing for Medicaid enrollees. JAMA Intern Med,178(5), 673-679.
https://doi.org/10.1001/jamainternmed.2018.1007
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nislo, M., Duffy, S., Hernandez, A. V.,
Keurenties, C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood, M., &
Kleijen, J. (2015). Cannabinoids for medical use: A systematic review and meta-analysis.
JAMA, 313(24), 2456-2473. https://doi.org//10.1001.jama.2015.6358.
Woodbury, A. (2015). Opioids for nonmalignant chronic pain. AMA J Ethics, 17(3), 202-208.
https://doi.org//10.1001/journalofethics.2015.17.3.ecas1-1503
Zaller, N., Topletz, A., Frater, S., Yates, G., & Lally, M. (2015). Profiles of medicinal cannabis
patients attending compassion centers in Rhode Island. Journal of Psychoactive Drugs,
47(1), 18–23. https://doi.org/10.1080/02791072.2014.999901
Zelaya, C. E., Dahlhamer, J. M., Lucas J. W., & Connor, E. M. (2020). Chronic pain and highimpact chronic pain among U.S. adults. NCHS Data Brief No. 390.
https://www.dcc.gov/nchs/products/databriefs/db390.htm

Appendix
Table 1
Database Search Description
Database
(or Search Engine)
1. PubMed

2. EBSCO Host,
including
Academic
Search
Premier,
CINAHL Plus
with Full-Text,
Cochrane
Central
Register of
Controlled
Trials,
Cochrane
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Collaboration and others, as part of an international effort to
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Bold numbers include studies to which inclusion/exclusion criteria applied.
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Rationale
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Olmstead, T. A., Yonkers, K. A., Ondersma, S. J., Forray, A.,
Gilstad, H. K., & Martino, S. (2019). Cost‐effectiveness of
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Cross-sectional study of illicit drug use by
women seeking care at reproductive health
centers.

Orhurhu, V., Olusunmade, M., Urits, I., Viswanath, O., Peck, J.,
Orhurhu, M. S., Adekoya, P., Hirji, S., Sampson, J., Simopoulos, T.,
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663. https://doi.org/10.1111/papr.12789

Excluded

Secondary analysis of patients hospitalized for
chronic pain to assess prevalence of opioid use
disorder. Does not specify whether opioid use
disorder is from prescription or illicit opioids.

Monti, L., Stefanucci, A., Pieretti, S., Marzoli, F., Fidanza, L.,
Mollica, A., Mirzaie, S., Carradori, S., De Petrocellis, L., Schiano
Moriello, A., Benyhe, S., Zádor, F., Szűcs, E., Ötvös, F., Erdei, A. I.,
Samavati, R., Dvorácskó, S., Tömböly, C., &
Novellino, E. (2016). Evaluation of the analgesic effect of 4anilidopiperidine scaffold containing ureas and carbamates. Journal
of Enzyme Inhibition & Medicinal Chemistry, 31(6), 1638–1647.
https://doi.org/10.3109/14756366.2016.1160902

Research paper on fentanyl analogs and their
analgesic effects.

Reference

Inclusion
or
Exclusion
Excluded

Rationale

Rogers, A. H., Shepherd, J. M., Paulus, D. J., Orr, M. F., Ditre, J.
W., Bakhshaie, J., & Zvolensky, M. J. (2019). The interaction of
alcohol use and cannabis use problems in relation to opioid misuse
among adults with chronic pain. International Journal of Behavioral
Medicine, 26(5), 569–575. https://doi.org/10.1007/s12529-01909813-3

Excluded

Focused on misuse of cannabis and opioids.

Sanger, N., Bhatt, M., Shams, I., Shahid, H., Luo, C., Tam, S. L.,
Samaan, M. C., de Souza, R., Thabane, L. & Samaan, Z. (2018).
Association between socio-demographic and health functioning
variables among patients with opioid use disorder introduced by
prescription: A prospective cohort study. Pain Physician, 21(6),
E623-E632.

Excluded

Subject is opioid use disorder.

Shah, A., Hayes, C. J., Lakkad, M., & Martin, B. C. (2019). Impact
of medical marijuana legalization on opioid use, chronic opioid use,
and high-risk opioid use. JGIM: Journal of General Internal
Medicine, 34(8), 1419–1426. https://doi.org/10.1007/s11606-0184782-2

Included

Retrospective analysis of correlation between
medical marijuana usage and prescription opioid
use.

Park, J. N., RouhaniI, S., Beletsky, L., Vincent, L., Saloner, B., &
Sherman, S. G. (2020). Situating the continuum of overdose risk in
the social determinants of health: A new conceptual framework.
Milbank Quarterly, 98(3), 700–746. https://doi.org/10.1111/14680009.12470

Policy proposal regarding solutions to the (nonprescription) opioid epidemic.

Reference

Inclusion
or
Exclusion
Included

Rationale

Sohler, N. L., Starrels, J. L., Khalid, L., Bachhuber, M. A., Arnsten,
J. H., Nahvi, S., Jost, J., & Cunningham, C. O. (2018). Cannabis use
is associated with lower odds of prescription opioid analgesic use
among HIV-Infected individuals with chronic pain. Substance Use &
Misuse, 53(10), 1602–1607.
https://doi.org/10.1080/10826084.2017.1416408

Included

Secondary data analysis of rate of prescription
opioid use by people with HIV and chronic pain
and concomitant use of illicit drugs, including
cannabis.

Vigil, J. M., Stith, S. S., Adams, I. M., & Reeve, A. P. (2017).
Associations between medical cannabis and prescription opioid use
in chronic pain patients: A preliminary cohort study. PLoS ONE,
12(11), 1–13. https://doi.org/10.1371/journal.pone.0187795

Included

Cohort study of individuals enrolled in medical
cannabis program in New Mexico and
prescription opiate use.

Wall, M. M., Liu, J., Hasin, D. S., Blanco, C. & Olfson, M. (2018).
Use of marijuana exclusively for medical purposes. Drug Alcohol
Depend, (195),13-15.
https://doi.org/10.1016/j.drugalcdep.2018.11.009

Excluded

Examines non-prescription opiate use disorder.

Wen, H. & Hockenberry, J. M. (2018). Association of medical and
adult-use marijuana laws with opioid prescribing for Medicaid
enrollees. JAMA Intern Med, 78(5), 673-679.
https://doi.org/10.1001/jamainternmed.2018.1007

Included

Cross-sectional study of Medicaid enrollees who
were prescribed opioids during implementation
of state medical cannabis laws

Zaller, N., Topletz, A., Frater, S., Yates, G., & Lally, M. (2015).
Profiles of medicinal cannabis patients attending Compassion
Centers in Rhode Island. Journal of Psychoactive Drugs, 47(1), 18–
23. https://doi.org/10.1080/02791072.2014.999901

Included

Cross-sectional study of medicinal cannabis
patients as to why they were prescribed cannabis.

Sinha, C. B., Bakshi, N., Ross, D. & Krishnamurti, L. (2019).
Management of chronic pain in adults living with sickle cell disease
in the era of the opioid epidemic: A qualitative study. JAMA Netw
Open, 2(5). https://doi.org/10.1001/jamanetworkopen.2019.4410

Qualitative study of adults with sickle cell
disease and chronic pain who were prescribed
opioids.

Table 4
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Purpose of
the Study

Population
(p)/
Number
(n)/
Setting (s)

Study
Type
and
Level of
Evidence

Instruments
and Variables

Findings

Implications

Bachhuber, M.,
Arnsten, J. H., & Wurm,
G. (2019). Use of
cannabis to relieve pain
and promote sleep by
customers at an adult use
dispensary. Journal of
Psychoactive Drugs,
51(5), 400–404.
https://doi.org/10.1080/02
791072.2019.1626953

Determine
why adult
recreational
cannabis
users were
purchasing
cannabis.

Crosssectional
study

I: Electronic
survey.
V: N/A

65% of respondents purchased
cannabis to relieve pain. Of
those taking opioid analgesics,
88% reduced their dose of or
stopped taking opioids.

Many adults
purchasing nonmedical
cannabis
through
dispensaries are
using it to
control pain.
Opioid use in
these adults has
decreased.

Baron, E. P., Lucas, P.,
Eades, J. & Hogue O.
(2018). Patterns of
medicinal cannabis use,
strain analysis, and
substitution effect among
patients with migraine,
headache, arthritis, and
chronic pain in a
medicinal cannabis

To identify
patterns of
cannabis
treatment in
migraine and
headache, as
compared to
arthritis and
chronic pain,
and to

p= Adults
purchasing
recreational
cannabis
who did
not have
medical
certificatio
n/
n=1000/
s=2
cannabis
dispensarie
s in
Colorado
p=
Canadian
medical
cannabis
users
registered
through
Tilray, a
federally
authorized

I: Electronic
survey.
Migraine
patients were
additionally
administered the
ID Migraine
questionnaire.
V: NA

Chronic pain was the most
common reason for cannabis
use. Of the chronic pain users
of cannabis, 72% of opiate
users reported substituting
opiate use with cannabis use.

More people
with chronic
pain than any
other condition
reported using
medical
cannabis for
symptom
control, of these
users, the

Level VI

Crosssectional
cohort
study
Level IV

Citation

Purpose of
the Study
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Number
(n)/
Setting (s)

cohort. J Headache Pain,
19(1),37. https://doi.org/
10.1186/s10194-0180862-2

analyze
preferred
strains,
biochemical
profiles, and
substitution
of prescribed
medications
with
cannabis.
Investigate
cannabis use
in people
living with
chronic noncancer pain
who had been
prescribed
opioids,
including
their reasons
for use and
perceived
efficacy of
cannabis;
associations
between
amount of
cannabis use
and pain,

cannabis
production,
distribution
and
research
company in
Canada.
n=2032.

Campbell, G., Hall,
W.D., Peacock, A.,
Lintzeris, N., Bruno, R.,
Larance, B., Nielsen, S.,
Cohen, M., Chan, G.,
Mattick, R.P., Blyth, F.,
Shanahan, M., Dobbins,
T., Farrell, M. &
Degenhardt, L. (2018).
Effect of cannabis use, in
people with chronic noncancer pain prescribed
opioids: Findings from a
4-year prospective cohort
study. Lancet Public
Health, 3(7),e341-e350.
https://doi.org
10.1016/S24682667(18)30110-5

p=Australia
ns with
chronic
pain and
prescriptio
ns for
opioids.
n=1514
s= patients
were
recruited
through
community
pharmacies

Study
Type
and
Level of
Evidence

Instruments
and Variables

Findings

Implications

majority who
also were using
opioids were
able to
substitute these
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Crosssectional
cohort
study
Level IV

I: Baseline
interviews with
phone or selfadministered
questionnaire
follow-up
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V: Outcome:
pain severity
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generalized
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in prescribed
opioid dose and
discontinuation
of opioids.
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temporal relationship between
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cannabis use reduced prescribed
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people with
chronic noncancer pain who
had been
prescribed
opioids,
but there was no
evidence that
cannabis use
improved
patient
outcomes.

Citation

Ishida, J. H., Wong, P.
O., Cohen, B. E., Vali,
M., Steigerwald, S., &
Keyhani, S. (2019).
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for opioids in
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opioids for
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Study
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and
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Evidence
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Implications
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representative
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opioids, which
included a
substantial
degree of opioid
discontinuation
(~20%), was
common. Better
self-reported
pain
management

Exposure:
Cannabis use.

P= 16,280
randomly
selected
US adults
sent a
survey
regarding
marijuana
and
prescriptio
n opioid
use.
n=9003
respondent
s. Of those,
486

Crosssectional,
cohort
study
Level IV

I: Electronic
survey. Prior to
administration,
survey was
tested on a
convenience
sample of 40
adults to ensure
question
reliability and
validity.
V: Outcome:
Amount of
opiate use
Exposure:
cannabis use.
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1. Describe
the
demographic
s of medical
cannabis user
and their use
of
prescription
drugs,
alcohol,
tobacco, and
illicit
substances.
2. Assess the
pattern of
substitution
of cannabis
for other
substances
and drugs.
3. Assess
factors
influencing

p=
Canadian
medical
cannabis
users
registered
through
Tilray, a
federally
authorized
cannabis
production,
distribution
and
research
company in
Canada.
n=2032.

Crosssectional
cohort
study
Level IV

I: 239 question
survey.
V: Outcome:
Change in use of
prescribed
opioids
Exposure:
Medical
cannabis.
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and fewer side
effects and
withdrawal
symptoms were
the most
common reasons
for substitution.
The most commonly cited
The findings
substitution was for prescription provide insight
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and the
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reported impacts
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on the use of
610 mentions of specific opioid opioids,
medications, patients report
suggesting that
total cessation of use of 59.3%
increased
(n = 362).
regulated access
to medical and
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result in a
reduction in the
use of and
subsequent
harms
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Case study of
weaning
postoperative
patient with
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chronic pain
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by
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g pain control
with
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To
investigate
whether
marijuana
use among
PLWH
(people
living with
HIV) who
have chronic

Implications

associated with
opioids.
n=1
s=liver
transplant
patient who
was on
opiates
prior to
surgery for
chronic
pain and
who was
attempting
to wean
down his
opiate use
after
discharge.
p=433
PLWH and
chronic
pain.
n=120 of
this subset
of PLWH
and chronic
pain who
also used

Case
report

NA

Reductions in opioid
consumption were
achieved with the
administration of medical
cannabis in
a patient with acute
postoperative pain
superimposed on
a chronic pain syndrome and
receiving high doses of
opioids. Cannabis started at 6
weeks post-op and at 5 months
post-op was down to 6 mg/day
from 30 mg/day of
hydromorphone and functional
status was excellent.

Highlights
potential of
adjuvant
cannabis therapy
to help in
weaning patients
from prescribed
opioids.

I: Self-reported
measures of
chronic
pain and
marijuana use at
an index visit
and follow up
for 1 year in the
Center for AIDS
Research

Neither increases nor decreases
in marijuana use were
associated with changes in pain
severity, and
marijuana use was not
associated with either lower
odds of opioid
initiation or higher odds of
opioid discontinuation.

The researchers
did not find
evidence that
marijuana use in
PLWH and
chronic pain is
associated with
improved pain
outcomes or
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marijuana
in the past
three
months.
s=establish
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in the
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system.

pain and
HIV
outcomes
embedde
d within
the
Centers
for AIDS
Research
Network
of
Integrate
d Clinical
Systems
(CNICS).

Network of
Integrated
Clinical Systems
(CNICS).
V: Exposure:
Self-reported
marijuana use.
Outcome:
Changes in pain
and initiation or
discontinuation
of opioids
during the study
period.
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C. (2019). Impact of
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To
investigate
the
correlation
between
medical
marijuana
usage and
prescription
opioid use.

p= A 10%
sample of a
nationally
representati
ve
database of
commercial
ly insured
population
was used to
gather
information
on opioid

Level IV
Secondar
y data
analysis
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study
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I: NA
V: Exposure
variable:
whether medical
marijuana laws
were in effect
during the year.
Outcome
variables:
prescription
opioid use,
chronic opioid
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reduced opioid
prescribing.

In the fully adjusted analyses,
MML was associated with a
lower probability of opioid use,
chronic opioid use
and high-risk opioid use.

Medical
marijuana
legalization was
associated with
lower
odds of opioid
use, chronic
opioid use, and
high-risk opioid
use when
controlling for
many state-level
and patient-level
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Ross, D. & Krishnamurti,
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To evaluate
participants
perceptions
of any
changes to
their pain
management
associated
with the 2016
guidelines
from the
Centers for
Disease
Control and
Prevention.

p= Adults
with sickle
cell
disease.
N=15.
s=patients
recruited
from
national
sickle cell
conference
and two
sickle cell
clinics.

Qualitati
ve study.

I: Semistructured phone
interviews.
V: NA

The opioid
epidemic may
have negatively
affected
patients’ care by
increasing
barriers to
opioids.
Patients felt that
they lacked
access to nonopioid options,
including
medical
cannabis.

Sohler, N. L., Starrels, J.
L., Khalid, L.,
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Arnsten, J. H., Nahvi, S.,
Jost, J., & Cunningham,
C. O. (2018). Cannabis
use is associated with
lower odds of
prescription opioid
analgesic use among
HIV-Infected individuals
with chronic pain.

To explore
patterns of
use of
cigarette,
alcohol, and
illicit drugs
in HIVinfected
people with
chronic pain
who were

p= 459
adults
infected
with HIV
who
reported
chronic
pain.
n= 371
who
reported

Secondar
y data
analysis
of cohort
study

Participants reported that
recently their opioid
prescriptions had become more
restrictive, were more closely
monitored, and were
increasingly difficult to fill in
pharmacies. Participants also
described increased
stigmatization about opioid use
and that their medical care was
being affected by the
physician’s exclusive focus on
reducing pain medication use.
There was an emerging interest
among adult patients in the
consideration of the use of
alternative therapies, including
marijuana, to manage pain.
Analysis of cigarette, alcohol,
and illicit drug use patterns
found that only cannabis use
was independently associated
with prescribed opioid
analgesic use after adjusting
for potential confounders and
other substance use. Compared
with nonusers, those who
reported cannabis use
were significantly less likely to
report prescribed opioid

Level VI

Level IV

I: Interview
questionnaire
consisting of 31
questions.
Interviews
conducted in
private setting in
office or over
phone.
V: Outcome:
Current use of a

Findings
provide
evidence of an
association
between
cannabis use
and reduced
opioid analgesic
use.
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prescribed
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Adams, I. M., & Reeve,
A. P. (2017).

To examine
the relation
between

prescribed
opiate use.
s=
screening
interviews
conducted
as part of
Project
FIRST, a
randomized
trial of
abstinencereinforcing
financial
incentives
to improve
HIV
outcomes
among
HIVinfected
drug users
that was
conducted
in the
Bronx,
New York
p=people
Historica
with
l cohort
chronic

Instruments
and Variables

Findings
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prescribed
analgesic use.
opioid analgesic.
Exposure: selfreported
current use of
cigarettes,
alcohol, or illicit
drugs,
including
nonprescribed
opioid
analgesics,
cannabis,
heroin, and
cocaine (within
the past 30
days).

I: Prescription
Monitoring
Program opioid

Clinically and statistically
significant evidence of an
association between MCP

Evidence
regarding
decreased opioid
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enrollment in
the New
Mexico
Medical
Cannabis
(MMC)
program and
opioid
prescription
use.

pain who
were
prescribed
opioids.
n=37
enrolled in
MMC
program,
n=29 nonenrolled in
MMC

study.
Level 4.

enrollment and opioid
prescription cessation and
reduction. Survey responses
indicated improvements in pain
reduction, quality of life, social
life, activity levels, and
concentration, and few side
effects from using cannabis one
year after enrolling in the MCP.

use and
improved
quality of life
suggests
medical
cannabis should
be considered
for adults with
chronic pain.

Wen, H. & Hockenberry,
J. M. (2018). Association
of medical and adult-use
marijuana laws with
opioid prescribing for
Medicaid enrollees.
JAMA Intern Med,

To examine
the
association of
state
implementati
on of medical
and adult-use

p= all
Medicaid
fee-forservice and
managed
care
enrollees,

Quasiexperime
ntal
differenc
e-withindifferenc
es design

records
reviewed over a
21-month period
to measure
cessation
and reduction.
MCP patientreported
benefits and
side-effects of
using cannabis
one year after
enrollment were
also recorded.
V: Outcome:
cessation or
decrease in amt
of opioid
prescribed.
Exploratory:
Registration or
non-registration
in MMC.
I: NA
V: outcome
Opioid
prescribing rate,
measured as the
number of
opioid

State implementation of
medical marijuana laws was
associated with a 5.88% lower
rate of opioid prescribing. The
implementation of adult-use
marijuana laws, which all
occurred in states with existing
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states that
allowed both
medical and
adult
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marijuana
laws with
opioid
prescribing
rates and
spending
among
Medicaid
enrollees

who are a
high-risk
population
for chronic
pain,
opioid use
disorder,
and opioid
overdose.

(adjusted
pre-post
trend
differenc
e
analysis)

medical marijuana laws, was
associated with a 6.38% lower
rate of opioid prescribing.

recreational
marijuana.

To
investigate
sociodemographic
s and reasons
for medicinal

n=1059
statequarter
reports of
State Drug
Utilization
Data from
the Centers
for
Medicare
and
Medicaid
Services
(CMS)
p=medical
cannabis
dispensary
patients in
Rhode
Island who

prescriptions
covered by
Medicaid on a
quarterly, per1000-Medicaidenrollee basis.
Exposure: State
implementation
of medical and
adult-use
marijuana laws.

I: survey which
included
assessment of
pain interference
using the Brief

69% of participants reported
experiencing chronic pain and
described feeling “much better”
with the use of medicinal
marijuana (85%). 92%

The majority of
study
participants
sought to obtain
relief from
chronic pain and

Zaller, N., Topletz, A.,
Frater, S., Yates, G., &
Lally, M. (2015). Profiles
of medicinal cannabis
patients attending
compassion centers in
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patients in
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were
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two
Compassio
n Centers
(medical
dispensarie
s)
n=200
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Pain Inventory
(BPI).
V: NA

considered medicinal marijuana
to have fewer unwanted
side-effects than conventionally
prescribed pain management
medications. >50% of
participants reported using
cannabis in place of
prescription drugs or were
making serious attempts to
wean off high doses of
prescription drugs, such as
opioids prescribed for
chronic pain.

other
debilitating
chronic medical
illnesses through
use of medicinal
cannabis. Most
patients
interviewed
report that
medicinal
cannabis
improves their
pain
symptomology,
and are
interested in
alternative
treatment
options to
opioid-based
treatment
regimens.

